Veru (VERU)

• Market cap: $95M
• 1 day: 3.20%
• 5 days: -8.58%
• 1 month: 3.81%
• 3 months: -16.76%
• 6 months: -16.78%
• Year to date: -10.05%
• 1 year: -3.64%
• 5 years: -77.46%
• 10 years: -56.73%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Employees: 210

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

52% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 23

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

26% more call options, than puts

Call options by funds: $679K | Put options by funds: $540K

5% more funds holding

Funds holding: 105 [Q2] → 110 (+5) [Q3]

2.37% less ownership

Funds ownership: 43.28% [Q2] → 40.91% (-2.37%) [Q3]

14% less capital invested

Capital invested by funds: $53.3M [Q2] → $46M (-$7.28M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 362% upside
• Avg. target: $4 516% upside
• High target: $5 670% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target	362% upside $3	Buy Reiterated	20 Dec 2024
Oppenheimer Leland Gershell 54% 1-year accuracy 31 / 57 met price target	670% upside $5	Outperform Reiterated	5 Nov 2024